Figure 1

Changes in clinical factors from baseline to 3 months later the initiation of ARNI in patients with pre-heart failure/heart failure. (a) BMI, (b) SBP, (c) DBP, (d) HR, (e) LVEF, (f) FBS, (g) Insulin, (h) HbA1c, (i) TG, (j) HDL, (k) LDL, (l) AST, (m) ALT, (n) LDH, (o) ALP, (p) γ-GTP, (q) TB, (r) Alb, (s) eGFR, (t) UA, (u) BNP, (v) NEFA, (w) TKB. N.S., not significant; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LVEF, left ventricular ejection fraction; FBS, fasting blood sugar; Hb, hemoglobin; TG, triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; γ-GTP, γ-glutamyltranspeptidase; TB, total bilirubin; Alb, albumin; eGFR, estimated glomerular filtration rate; UA, uric acid; BNP, B-type natriuretic peptide; NEFA, non-esterified fatty acid; TKB, total ketone body.